218449-30-0

Basic information

• Product Name: 2-aMino-2-(3,4-difluorophenyl)acetonitrile
• Synonyms: 2-aMino-2-(3,4-difluorophenyl)acetonitrile
• CAS NO: 218449-30-0
• Molecular Formula: C₈H₆F₂N₂
• Molecular Weight: 168.1434464
• Mol File: 218449-30-0.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 237.4±40.0 °C(Predicted)
• Appearance: /
• Density: 1.308±0.06 g/cm3(Predicted)
• PKA: 4.72±0.10(Predicted)
• CAS DataBase Reference: 2-aMino-2-(3,4-difluorophenyl)acetonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 2-aMino-2-(3,4-difluorophenyl)acetonitrile(218449-30-0)
• EPA Substance Registry System: 2-aMino-2-(3,4-difluorophenyl)acetonitrile(218449-30-0)

Safety Data

• Hazardous Substances Data: 218449-30-0(Hazardous Substances Data)

Upstream product

• 34036-07-2 3,4 difluorobenzaldehyde 
• 75-86-5 2-hydroxy-2-methylpropanenitrile 
• 7677-24-9 trimethylsilyl cyanide 
• 72235-53-1 3,4-difluorobenzylamine 

Downstream Products

• 225641-94-1 DL-(3,4-difluorophenyl)glycine 
• 277295-93-9 2-amino-2-(3,4-difluorophenyl)-ethanol 
• 225641-91-8 4-(3,4-difluorophenyl)-2-oxazolidinone 
• 218449-35-5 [1-(3,4-difluorophenyl)-2-hydroxy-ethyl]-carbamic acid-tert-butyl ester 
• 218450-42-1 4-(3,5-difluorophenyl)-5,5-dimethyl-2-oxo-oxazolidine 
• 218449-37-7 4-(3,4-difluorophenyl)-2-oxo-oxazolidine-3-carboxylic acid-4-nitro-phenyl ester 
• 277295-97-3 1-(3,4-difluorophenyl)-2-methyl-2-hydroxypropylamine 
• 218451-40-2 (+)-3-(3-(4-Aminocarbonyl-4-(4-chloro)phenylpiperidin-1-yl)-propyl)aminocarbonyl-4-(3,4-difluoro)phenyl-2-oxazolidinone 
• 218451-28-6 (+)-3-(3-(4-cyano-4-(2,4-dichloro)phenylpiperidin-1-yl)propyl)aminocarbonyl-4-(3,4-difluorophenyl)-2-oxazolidinone 
• 218449-31-1 amino-(3,4-difluorophenyl)-acetic acid methyl ester 

Relevant articles and documents

Facile Access to 1,4-Disubstituted Pyrrolo[1,2- a ]pyrazines from α-Aminoacetonitriles

An efficient and practical synthetic protocol for the synthesis of 1,4-disubstituted pyrrolo[1,2- a ]pyrazine derivatives is described that originates from α-substituted pyrroloacetonitriles which, in turn, are readily available from aryl and alkyl aldehydes. The α-pyrroloacetonitriles were subjected to a Friedel-Crafts acylation with methyl chlorooxoacetate followed by reduction of the nitrile group under Pd-catalyzed hydrogenation conditions and finally aromatization with DDQ leading to the desired pyrrolo[1,2- a ]pyrazine derivatives. This method was generalized and successfully applied to various aryl, heteroaryl, and alkyl substrates. The developed protocol provides direct and convenient access to 1,4-disubstituted ring systems in moderate to good overall yields (51-68percent) without the need for purification of the intermediates. Further functionalization via the stepwise halogenation (bromination, iodination) and nitration was also demonstrated. In addition, the potential of the ester functionality for elaboration was demonstrated by manipulating into heterocyclic ring systems, exemplified by conversion into benzoxazole derivatives.

Discovery of novel spiro-piperidine derivatives as highly potent and selective melanin-concentrating hormone 1 receptor antagonists

Optimization of high-throughput screening hit 1a led to the identification of a novel spiro-piperidine class of melanin-concentrating hormone 1 receptor (MCH-1R) antagonists. Compound 3c was identified as a highly potent and selective MCH-1R antagonist, which has an IC50 value of 0.09 nM at hMCH-1R. The synthesis and structure-activity relationships of the novel spiro-piperidine MCH-1R antagonists are described.

SUBSTITUTED ANILINIC PIPERIDINES AS MCH SELECTIVE ANTAGONISTS

This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therepeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.